Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tessa Straatmijer

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|September 14, 2023
[Inflammatory bowel disease]Tessa Straatmijer, Marjolijn Duijvestein
European Journal of Gastroenterology & Hepatology|January 6, 2021
Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitisTessa Straatmijer, Sara van Gennep, Marjolijn Duijvestein, et al.
Scandinavian Journal of Gastroenterology|December 3, 2023
Patient preferences in treatment options of ulcerative colitis: a discrete choice experimentTessa Straatmijer, M Elske van den Akker-van Marle, Cyriel Y Ponsioen, et al.
Digestive Diseases and Sciences|April 16, 2025
Obesity Is Associated with Inferior Clinical Treatment Outcomes in Inflammatory Bowel Disease: A Nationwide Dutch Registry StudyDorien Oomkens, Zlatan Mujagic, Annemarie de Vries, et al.
Digestive Diseases and Sciences|March 15, 2023
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's DiseaseTessa Straatmijer, Vince B C Biemans, Dirk Jan A R Moes, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2022
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseasesAdriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2022
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC RegistryTessa Straatmijer, Fiona D M van Schaik, Alexander G L Bodelier, et al.
Journal of Crohn'S & Colitis|April 28, 2021
Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort StudyTessa Straatmijer, Vince B C Biemans, Frank Hoentjen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 1, 2022
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry StudyTessa Straatmijer, Vince B C Biemans, Marijn Visschedijk, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nederlands Tijdschrift Voor Geneeskunde|September 14, 2023
[Inflammatory bowel disease]Tessa Straatmijer, Marjolijn Duijvestein
European Journal of Gastroenterology & Hepatology|January 6, 2021
Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitisTessa Straatmijer, Sara van Gennep, Marjolijn Duijvestein, et al.
Scandinavian Journal of Gastroenterology|December 3, 2023
Patient preferences in treatment options of ulcerative colitis: a discrete choice experimentTessa Straatmijer, M Elske van den Akker-van Marle, Cyriel Y Ponsioen, et al.
Digestive Diseases and Sciences|April 16, 2025
Obesity Is Associated with Inferior Clinical Treatment Outcomes in Inflammatory Bowel Disease: A Nationwide Dutch Registry StudyDorien Oomkens, Zlatan Mujagic, Annemarie de Vries, et al.
Digestive Diseases and Sciences|March 15, 2023
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's DiseaseTessa Straatmijer, Vince B C Biemans, Dirk Jan A R Moes, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2022
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseasesAdriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2022
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC RegistryTessa Straatmijer, Fiona D M van Schaik, Alexander G L Bodelier, et al.
Journal of Crohn'S & Colitis|April 28, 2021
Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort StudyTessa Straatmijer, Vince B C Biemans, Frank Hoentjen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 1, 2022
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry StudyTessa Straatmijer, Vince B C Biemans, Marijn Visschedijk, et al.
Pageof 1